Today’s AI Top Pick: PODD

7/10/2026 · Recently Alerted Turnaround screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Today's pick · Recently Alerted TurnaroundPODDBUY NOW8.6 / 107/10/2026

Insulet (PODD) is the cleanest confluence of screen thesis, forecast tape, and setup on this list. The multi-timeframe forecasts stack up hard beyond the very-near-term noise: 4h mid/long +62.3%/+102.8%, daily short/mid/long +25.0%/+67.5%/+54.9%, and weekly short/mid/long +7.1%/+66.8%/+80.4%. That is 1h through 1wk all pointing up on mid/long horizons with kronos bullish_prob = 1.0 and near_term_bullish = 0.8 — the exact multi-timeframe agreement the mandate asks for. Critically, PODD is NOT extended. The stock trades at $158.31 with a weekly position_in_21bar_range of 13.15% and weekly recent_21bar_pct of -34.55% — meaning it's washed out on the higher timeframe (down ~35% off the swing high) but stabilizing on the daily (pos_in_21bar_range 75.81%, +5.04% recent). That's exactly the 'turnaround pivot' geometry — bottom-of-range on the higher timeframe, base-building on the lower. Fundamentals are best-in-class for this cohort: fundamental_score 8, PE 36.8 / fwdPe 19.6, PEG 0.73, ROE 23%, profitMargin 10.4%, salesYoY +31.9%, epsNextY +24.5%, recom 1.43, targetUpsidePct +48.8%. This is a real, profitable, growing medtech — not a value trap. News is a mild net positive. The Omnipod 5 launch in Spain (Jul 10) is a concrete geographic expansion catalyst; the 'shares fell 47%' framing is retrospective (that's already priced in — it's why we're here). The 'analyst target cut' headline is a soft negative but does NOT rise to guidance cut, litigation, dilution, or short-seller — the disqualifying categories. Compare to FUTU (DOJ probe + class actions — landmine), ORCL (S&P debt downgrade to BBB- with $160B debt shadow), MLCO (Morgan Stanley downgrade to EW, PT $6 vs. $5.29 current), and ZG (FTC trial over Redfin apartment listings partnership) — all screen well but carry fresh, material headline drag. PODD does not. Entering TODAY vs. waiting: the 4h forecast short is only +0.43% (near-term neutral), which is why chasing isn't necessary — but the daily forecast short of +25% and weekly setup with 13% range-position give you asymmetric upside from here. A pullback below $155 is a gift, but the setup does not require it — the drawdown from weekly high (-35.8%) already IS the pullback.

Entry zone

$155–$160 (start half at $158.31 spot, add on any dip to $150–$153 which is the 4h dd zone)

Stop loss

$142 (below the 1wk consolidation base, ~10% risk, invalidates the weekly turnaround thesis)

First target

$195–$200 (aligns with daily fc_short +25% and reclaims prior daily range)

Longer target

$240–$260 (weekly fc_long +80% math implies ~$285; scaled conservatively for a swing target; also inside targetUpsidePct +48.8% consensus)

Risks

Recent analyst PT cut suggests estimate momentum is not yet inflecting — a fresh guide-down on next print could re-break the weekly range
PE 36.8 is not cheap even with 24.5% EPS growth; PEG 0.73 assumes execution — any Omnipod 5 uptake miss compresses multiple fast
Institutional ownership at 105% (heavy crowding/short interest embedded) with shortFloat 7.11% — squeezy but also crowded long if sentiment shifts
1h and 4h short-term forecasts are essentially flat (-0.55% / +0.43%), so a 2-5% shakeout before the daily/weekly move is very plausible
Medical device reimbursement/regulatory headline risk in EU markets tied to the Spain launch execution

Honorable mentions

HSAINear-term_bullish 1.0, all four TFs positive, 1d pos 41.57% (mid-range, not chasing), weekly range pos 12.73% (washed out). PEG 0.44, epsNextY +68.6%, salesYoY +44.1%, targetUpside +83%. Clean news. Lower conviction than PODD only because weekly forecast magnitudes are modest (long +1.88%) — the tape doesn't scream as loudly on the higher TF.

TMDXNear-term_bullish 1.0 with 4h/1d/1wk forecasts of +41.8/+59.5/+26.3 on mid horizons, weekly range pos 11.33% (deep pullback), ROE 45.2%, profit margin 27%. Docked for shortFloat 23% (crowded) and a recent Evercore PT cut to $90 — thesis intact but with a caution flag.

Full ranking (27)

#	Symbol	Verdict	Score	Read
1	PODD	BUY NOW	8.6	Multi-TF bullish stack (4h/1d/1wk fc_long +102/+55/+80), weekly range pos 13%, fund score 8, Omnipod 5 Spain launch catalyst — cleanest setup.
2	HSAI	BUY NOW	8.1	All-TF green forecasts, near-term 1.0, weekly pos 12.7%, PEG 0.44 with 44% sales growth and clean tape.
3	TMDX	BUY NOW	7.8	Near-term 1.0 with strong 4h/1d forecasts, weekly range pos 11%, elite ROE 45% — modest PT cut is the only wart.
4	ZG	BUY PULLBACK	7.4	Forecasts spectacular (1wk long +100%), near-term 1.0, but FTC trial headline is a genuine tail risk to hold at max size.
5	CALX	BUY PULLBACK	7.0	AI platform customer win and strong daily forecasts but daily/4h pos_in_range = 100% — chasing risk, wait for dip.
6	NAGE	BUY PULLBACK	6.8	Fund score 8, recom 1.0, NAD Pharma spinout catalyst, but 1wk forecasts are NEGATIVE (-26% mid/long) — mixed tape.
7	NOW	BUY PULLBACK	6.7	Daily fc_short +14.9, mid +41; but pos_in_range 98.5% daily = extended, wait for pullback.
8	TIGR	BUY PULLBACK	6.6	1d fc_short +93% is outlier-strong, PE 7.8 / fwdPe 6.0, weekly pos 9.1% — very washed out but forecast magnitude looks anomalous.
9	ORCL	BUY PULLBACK	6.3	RSI 32 oversold, ROE 54%, but S&P downgrade to BBB- with $160B debt and weak 1wk forecast (fc_long +2.3%) — thesis wounded.
10	ONON	BUY PULLBACK	6.2	Clean fundamentals and positive analyst chatter, but forecast magnitudes are only modest across TFs.
11	BX	WAIT	6.1	Fund score 8 but weakest forecast magnitudes in the cohort (1wk fc_long only +6%) and Barclays PT cut.
12	PSIX	WAIT	6.0	Fund score 7.5, PE 7.8 with 61% EPS growth, but 1wk forecasts NEGATIVE (mid/long -50/-61%) — dangerous divergence.
13	CHWY	BUY PULLBACK	5.9	Strong 4h/1d/1wk forecasts and near-term 0.8, but Cramer 'too hard to own' and 1h at 100% of range.
14	MNTN	WAIT	5.7	bullish_prob null, 1h/4h forecasts negative on long, only 1d looks good — signal too fragmented.
15	SRAD	WAIT	5.6	Fund score 8 but 1wk forecasts negative (-24/-14) — screen strong, tape rolling over.
16	GENI	BUY PULLBACK	5.5	Near-term 0.8, huge epsNextY off low base, but negative margins and 1h/4h forecasts weak; wait for setup.
17	RBBN	WAIT	5.4	1d fc +20/+29/+37 constructive but sales YoY -1.15% and small cap — fundamentals thin.
18	MLCO	AVOID	5.2	Morgan Stanley downgrade to EW with PT $6 (near current $5.29), near_term_bullish 0 — screen passes but tape/news don't.
19	SE	WAIT	5.1	RSI 72.4, daily pos 100% — screaming overbought, 1h/4h short forecasts negative. Chase risk.
20	FUTU	AVOID	4.9	DOJ probe and class actions is exactly the disqualifying landmine — great fundamentals not worth the tail risk today.
21	BESS	WAIT	4.8	No margins/sales data, 1h fc_long -43% but 1wk fc_long +164% — signals contradict; too speculative.
22	ARES	WAIT	4.7	Multiple analyst PT cuts (Barclays/Citizens), fund score 5.5, modest forecast magnitudes.
23	TOST	WAIT	4.6	bullish_prob only 0.4, near_term 0.2, RSI 62.9; Goldman upgrade is a positive but tape not aligned.
24	CELH	WAIT	4.4	PT cuts and stock trading down per headlines; forecasts constructive but news dragging.
25	HNI	AVOID	4.3	ROE 0.11%, profitMargin 0.04%, StockStory 'plummet' and 'warning signs' headlines — quality trap.
26	JBI	AVOID	4.0	StockStory '3 Reasons to Sell JBI' + salesYoY -2.54% + 'warning signs' — thesis broken.
27	SDA	AVOID	3.6	PE 522, $96M cap, instOwn 0.31%, weekly fc +685% is a lottery-ticket outlier — not investable size.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord